ModraPac005, a tablet formulation of paclitaxel developed by Modra, is currently undergoing Phase I studies. Paclitaxel, a member of the taxane class of chemotherapeutics, is also one of the most frequently applied anti-cancer drugs globally and shares a similar efficacy and toxicity profile with docetaxel. Paclitaxel is generally considered slightly less toxic and also requires IV- administration that is formulated with the toxic excipients chremophor EL and ethanol.
With initial focus on taxane-based chemotherapeutics, we will bring our oral formulation technology to other areas of oncology and work together with cancer leaders and innovators to expedite the development of next-generation cancer regimens.



Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial
Read more

Modra's Unique Approach

improving patient lives    
Learn more


Meet us at one of the following events:      
Read more